RxDoctor Payments Data

Nathaniel Haddock, MD

Internal Medicine · Juneau, AKNPI 1659397065

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.2% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AstraZeneca at 30.0% of the total.

$1,423in general payments, 2019–2025

Across 63 payments — averaging $22.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$427
  • GSK$188
  • Novartis$163
  • AbbVie$136
  • E.r. Squibb & Sons, L.L.C.$119
  • Novo Nordisk$97
  • plus $293 from 7 others

What the payments were for

  • Food & beverage$1,32793%
  • Education$977%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,423 in reported general payments places this provider in the 85th percentile of 124 internal medicine providers in Alaska.

See all internal medicine providers in Alaska

Medicare billing

Part B allowed, 2024
$388,898
Medicare patients
576
Services billed
6,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin166$236,465
EliquisApixaban191$233,928
FarxigaDapagliflozin Propanediol149$192,296
OpdivoNivolumab12$188,425
MounjaroTirzepatide144$177,530
OzempicSemaglutide145$176,492
XareltoRivaroxaban73$112,442
BiktarvyBictegrav/Emtricit/Tenofov Ala12$48,754
JanuviaSitagliptin Phosphate30$46,858
MyrbetriqMirabegron74$45,602
WegovySemaglutide17$34,413
DapagliflozinDapagliflozin Propanediol25$33,705
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$33,024
Victoza 3-PakLiraglutide13$23,306
EntrestoSacubitril/Valsartan12$20,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$37$239,044202 claims
Novo NordiskOzempic, Wegovy$97$210,905162 claims
Lilly USA, LLCMounjaro, Trulicity$66$197,372156 claims
AstraZenecaFarxiga, Pulmicort Flexhaler$427$195,397161 claims
E.r. Squibb & Sons, L.L.C.Opdivo$119$188,42512 claims
GSKTrelegy Ellipta, Breo Ellipta$188$49,23739 claims
NovartisEntresto$163$20,31212 claims
AbbVieLumigan$136$3,87513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 124 internal medicine providers in Alaska.

Other internal medicine in Juneau

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →